vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Hims & Hers Health, Inc. (HIMS). Click either name above to swap in a different company.
Hims & Hers Health, Inc. is the larger business by last-quarter revenue ($617.8M vs $359.9M, roughly 1.7× AdvanSix Inc.). Hims & Hers Health, Inc. runs the higher net margin — 3.3% vs -0.8%, a 4.1% gap on every dollar of revenue. On growth, Hims & Hers Health, Inc. posted the faster year-over-year revenue change (28.4% vs 9.4%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-2.5M). Over the past eight quarters, Hims & Hers Health, Inc.'s revenue compounded faster (49.0% CAGR vs 3.4%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Hims & Hers Health, Inc. is an American telehealth company established in 2017. The company provides prescription medications, over-the-counter medications, and personal care products.
ASIX vs HIMS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $617.8M |
| Net Profit | $-2.8M | $20.6M |
| Gross Margin | 7.6% | 71.9% |
| Operating Margin | -0.7% | 1.5% |
| Net Margin | -0.8% | 3.3% |
| Revenue YoY | 9.4% | 28.4% |
| Net Profit YoY | -892.9% | -20.8% |
| EPS (diluted) | $-0.11 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $359.9M | $617.8M | ||
| Q3 25 | $374.5M | $599.0M | ||
| Q2 25 | $410.0M | $544.8M | ||
| Q1 25 | $377.8M | $586.0M | ||
| Q4 24 | $329.1M | $481.1M | ||
| Q3 24 | $398.2M | $401.6M | ||
| Q2 24 | $453.5M | $315.6M | ||
| Q1 24 | $336.8M | $278.2M |
| Q4 25 | $-2.8M | $20.6M | ||
| Q3 25 | $-2.6M | $15.8M | ||
| Q2 25 | $31.4M | $42.5M | ||
| Q1 25 | $23.3M | $49.5M | ||
| Q4 24 | $352.0K | $26.0M | ||
| Q3 24 | $22.3M | $75.6M | ||
| Q2 24 | $38.9M | $13.3M | ||
| Q1 24 | $-17.4M | $11.1M |
| Q4 25 | 7.6% | 71.9% | ||
| Q3 25 | 6.8% | 73.8% | ||
| Q2 25 | 14.3% | 76.4% | ||
| Q1 25 | 14.2% | 73.5% | ||
| Q4 24 | 3.4% | 76.8% | ||
| Q3 24 | 14.4% | 79.2% | ||
| Q2 24 | 17.9% | 81.3% | ||
| Q1 24 | 0.9% | 82.4% |
| Q4 25 | -0.7% | 1.5% | ||
| Q3 25 | -0.9% | 2.0% | ||
| Q2 25 | 7.7% | 4.9% | ||
| Q1 25 | 7.7% | 9.9% | ||
| Q4 24 | -3.9% | 3.9% | ||
| Q3 24 | 7.5% | 5.6% | ||
| Q2 24 | 11.5% | 3.5% | ||
| Q1 24 | -7.0% | 3.6% |
| Q4 25 | -0.8% | 3.3% | ||
| Q3 25 | -0.7% | 2.6% | ||
| Q2 25 | 7.7% | 7.8% | ||
| Q1 25 | 6.2% | 8.4% | ||
| Q4 24 | 0.1% | 5.4% | ||
| Q3 24 | 5.6% | 18.8% | ||
| Q2 24 | 8.6% | 4.2% | ||
| Q1 24 | -5.2% | 4.0% |
| Q4 25 | $-0.11 | $0.08 | ||
| Q3 25 | $-0.10 | $0.06 | ||
| Q2 25 | $1.15 | $0.17 | ||
| Q1 25 | $0.86 | $0.20 | ||
| Q4 24 | $0.02 | $0.10 | ||
| Q3 24 | $0.82 | $0.32 | ||
| Q2 24 | $1.43 | $0.06 | ||
| Q1 24 | $-0.65 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $228.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $815.2M | $540.9M |
| Total Assets | $1.7B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.8M | $228.6M | ||
| Q3 25 | $23.7M | $345.8M | ||
| Q2 25 | $18.4M | $1.1B | ||
| Q1 25 | $8.3M | $273.7M | ||
| Q4 24 | $19.6M | $220.6M | ||
| Q3 24 | $17.3M | $165.5M | ||
| Q2 24 | $12.1M | $129.3M | ||
| Q1 24 | $20.6M | $105.2M |
| Q4 25 | $815.2M | $540.9M | ||
| Q3 25 | $818.2M | $581.0M | ||
| Q2 25 | $823.7M | $562.7M | ||
| Q1 25 | $794.4M | $549.3M | ||
| Q4 24 | $774.6M | $476.7M | ||
| Q3 24 | $766.4M | $440.1M | ||
| Q2 24 | $746.6M | $362.0M | ||
| Q1 24 | $713.2M | $344.5M |
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.6B | $1.9B | ||
| Q1 25 | $1.6B | $891.7M | ||
| Q4 24 | $1.6B | $707.5M | ||
| Q3 24 | $1.5B | $602.3M | ||
| Q2 24 | $1.5B | $480.5M | ||
| Q1 24 | $1.5B | $448.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $61.3M |
| Free Cash FlowOCF − Capex | $36.1M | $-2.5M |
| FCF MarginFCF / Revenue | 10.0% | -0.4% |
| Capex IntensityCapex / Revenue | 7.7% | 10.3% |
| Cash ConversionOCF / Net Profit | — | 2.98× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $57.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.7M | $61.3M | ||
| Q3 25 | $26.6M | $148.7M | ||
| Q2 25 | $21.1M | $-19.1M | ||
| Q1 25 | $11.4M | $109.1M | ||
| Q4 24 | $64.2M | $86.4M | ||
| Q3 24 | $57.3M | $85.3M | ||
| Q2 24 | $50.2M | $53.6M | ||
| Q1 24 | $-36.2M | $25.8M |
| Q4 25 | $36.1M | $-2.5M | ||
| Q3 25 | $66.0K | $79.3M | ||
| Q2 25 | $-7.2M | $-69.5M | ||
| Q1 25 | $-22.6M | $50.1M | ||
| Q4 24 | $29.8M | $59.5M | ||
| Q3 24 | $26.8M | $79.4M | ||
| Q2 24 | $16.7M | $47.6M | ||
| Q1 24 | $-71.6M | $11.8M |
| Q4 25 | 10.0% | -0.4% | ||
| Q3 25 | 0.0% | 13.2% | ||
| Q2 25 | -1.7% | -12.8% | ||
| Q1 25 | -6.0% | 8.5% | ||
| Q4 24 | 9.1% | 12.4% | ||
| Q3 24 | 6.7% | 19.8% | ||
| Q2 24 | 3.7% | 15.1% | ||
| Q1 24 | -21.3% | 4.3% |
| Q4 25 | 7.7% | 10.3% | ||
| Q3 25 | 7.1% | 11.6% | ||
| Q2 25 | 6.9% | 9.3% | ||
| Q1 25 | 9.0% | 10.1% | ||
| Q4 24 | 10.4% | 5.6% | ||
| Q3 24 | 7.7% | 1.5% | ||
| Q2 24 | 7.4% | 1.9% | ||
| Q1 24 | 10.5% | 5.0% |
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | 9.43× | ||
| Q2 25 | 0.67× | -0.45× | ||
| Q1 25 | 0.49× | 2.20× | ||
| Q4 24 | 182.29× | 3.32× | ||
| Q3 24 | 2.57× | 1.13× | ||
| Q2 24 | 1.29× | 4.03× | ||
| Q1 24 | — | 2.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
HIMS
Segment breakdown not available.
